New approach targets immune system to fight returning brain tumors
NCT ID NCT02669173
Summary
This early-stage study tested whether two existing drugs, given at low doses, could help control aggressive brain tumors that have returned after previous treatment. The goal was to see if the drugs could reduce certain immune cells that suppress the body's natural defenses against the cancer. Researchers enrolled 12 patients with recurrent glioblastoma to assess safety and gather initial evidence of whether this approach might slow tumor growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Cleveland, Ohio, 44195, United States
Conditions
Explore the condition pages connected to this study.